Half-life

—

Tmax

—

Category

peptide

AOD-9604 is a synthetic C-terminal fragment of human growth hormone (amino acids 177-191) that has been investigated for its purported lipolytic activity. The proposed mechanism is independent of the GH receptor, instead acting through direct stimulation of adipocyte lipolysis via the beta-adrenergic pathway. Its half-life is approximately 2 hours. AOD-9604 has been studied in clinical trials for obesity but has not received FDA approval. Users tracking AOD-9604 should document dosing, injection sites, and weight or body-composition changes over time.

Mechanism

A synthetic peptide fragment derived from the C-terminal region of human growth hormone. In preclinical work it has been studied for possible effects on fat metabolism without the full growth-promoting activity of intact growth hormone. Human mechanistic data are limited.

Research summary

Early human trials evaluated it for obesity but did not establish clear efficacy, and it is not FDA-approved for weight management. Most supportive evidence is preclinical. Claims should be read against that evidence gap.

Reported side effects

Early trials reported general tolerability, but controlled long-term human safety data are limited. Sourcing and purity are recurring quality concerns.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Safety and metabolism of AOD9604 · Journal of Endocrinology and MetabolismNon-clinical PK only; no human half-life published. Vendor figures conflict and are not used.

References

AOD-9604 clinical trialDOI: 10.1530/eje.0.1480101

TrackPep slouží ke sledování záznamů. Zaznamenává, co zadáte, a nikdy nedoporučuje ani nevypočítává množství.